Alexandra Sakatos

Alexandra Sakatos has a diverse work experience, starting with their current position as Co-Founder & CEO of Ancilia Biosciences. At Ancilia, they are leading a team to develop a new class of live biotherapeutics using CRISPR technology. Prior to that, they were a Venture Founder at Deep Science Ventures, where they likely gained experience in the startup and venture capital space.

Alexandra also has experience in research and product development, having worked as a Research & Product Development Associate at Applied Biological Laboratories Inc. Alexandra contributed to the company for a year.

Alexandra Sakatos has an extensive background in academia, starting with their work as a Doctoral Researcher at Harvard University, where they made significant contributions from September 2010 to May 2016. Alexandra also served as a Philanthropy Advisory Fellow and participated in the TransMed Program during their time at Harvard.

Alexandra began their research career at the Salk Institute for Biological Studies as a Research Assistant from August 2007 to June 2010, gaining valuable laboratory experience. Additionally, they were an Analytics Intern at Columbia University in the City of New York in the summer of 2009, where they likely gained skills in data analysis.

Alexandra Sakatos obtained a Ph.D. in Biological Sciences (Microbiology) from Harvard University, completing their studies from 2010 to 2016. Prior to that, they attended Carleton College from 2003 to 2007, earning a B.A. in Neuroscience.